February 2019

Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, kicks off his second year as editor-in-chief by welcoming 6 industry experts on as section editors.

A shocking find on a CT scan leads to an unexpected diagnosis.

Although dalbavancin is currently approved by the US Food and Drug Administration for the treatment of skin and soft tissue infections, its distinctive pharmacokinetic profile has piqued curiosity regarding its place in therapy for infections requiring long durations of antibiotics, such as osteomyelitis.

The treatment duration for uncomplicated gram-negative bloodstream infections (BSIs) has traditionally ranged from 7 to 14 days. However, recent retrospective studies and meta-analyses have observed no differences in clinical outcomes in patients treated with shorter courses compared with prolonged courses, especially with urinary sources of infection.